Repare Therapeutics' Gynecological Cancer Trial Shows Mixed Results, Beigene Inks $1.5B Deal for MAT2A Inhibitor
Key Insights
Repare Therapeutics' phase I trial of lunresertib and camonsertib in gynecological cancers with specific biomarkers showed mixed results, impacting stock prices.
Beigene (search) secured a global licensing agreement with CSPC for SYH-2039, a phase I MAT2A (search) inhibitor targeting solid tumors (search), for up to $1.5 billion.
A new study identifies inceptor as a novel insulin receptor that degrades insulin, potentially opening new avenues for diabetes (search) therapeutics.
Repare Therapeutics Inc. recently shared phase I data from the Mythic gynecologic expansion trial, which assessed the combination of lunresertib and camonsertib at the recommended phase II dose in patients with endometrial cancer (search) and platinum-resistant ovarian cancer (search). These patients harbored lunre-sensitizing biomarkers. Lunresertib is a first-in-class precision oncology small-molecule PKMYT1 (search) inhibitor, designed to target cell cycle regulation in Lunre BM-positive tumors, specifically those with CCNE1 amplifications or FBXW7 or PPP2R1A deleterious alterations. Camonsertib is an oral small-molecule inhibitor of ATR, potentially best-in-class. The market responded negatively to the news, with Repare's shares (NASDAQ:RPTX) declining significantly.
Beigene's Strategic Licensing Agreement
Beigene (search) Ltd. has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (search) for SYH-2039, a phase I selective methionine adenosyltransferase 2A (MAT2A (search)) inhibitor. The deal is valued at up to $1.5 billion. SYH-2039 is currently under investigation for the treatment of solid tumors (search). Under the terms of the agreement, Beigene gains exclusive rights to develop, manufacture, and commercialize SYH-2039 worldwide. CSPC will receive an initial payment of $150 million and is eligible for potential development milestone payments of up to $135 million, commercialization milestone payments reaching $1.5 billion, and sales-based royalties.
Novel Insulin Receptor Discovery
Researchers at the Helmholtz Institute have identified inceptor, a novel inhibitor of the insulin signaling pathway. This molecule functions by binding insulin and targeting it for degradation. According to Heiko Lickert, director of the Institute of Diabetes (search) and Regeneration Research at Helmholtz Munich, this discovery marks a significant advancement in understanding insulin regulation, as inceptor represents a new insulin receptor that degrades insulin. The findings were published in Nature Metabolism.
GC Biopharma Expands Plasma Business
GC Biopharma (search) Corp. is set to acquire Abo Holdings Inc. for approximately ₩138 billion (US$96.28 million) in cash. This acquisition is part of GC Biopharma's strategy to expedite the U.S. market entry of Alyglo (search) (IVIG-SN 10%), which received approval last year. The acquisition, expected to close on January 31, 2025, involves the purchase of 100 million shares. Abo Holdings, based in Irvine, California, specializes in collecting medical-grade blood plasma for biotherapeutic pharmaceutical applications.